100,000 patients in the U.S. have ascites due to advanced liver cirrhosis, with no approved drug to treat ascites. Jonathan Adams, CEO & CFO of BioVie Inc. (OTCQB: BIVI) discusses how the company is developing what they hope to be the first ever approved drug to treat ascites.